Nanoform small is powerful logo Nanoform small is powerful logo
  • Contact Us
  • About Nanoform
    About Nanoform
    • Vision, mission and values
    • Organization
      Board of Directors
      CEO and Management Team
    • Success stories
    • Corporate Responsibility
  • Technology
    Technology
    • CESS®
      STARMAP®
    • Biologics
      Formulations
    • Case studies
  • Services
    Services
    • GMP Manufacturing
  • Corporate Governance
    Corporate Governance
    • Corporate Governance Statements
      General meeting
      Annual General Meeting 2022
      General meetings
    • The Board of Directors
      Board of Directors
      Duties of the Board of Directors
      Authorisations
      Board committees
      Remuneration of the Board
    • CEO and Management Team
      Remuneration
      Audit
      Internal Control and Risk Management
      Code of conduct
    • Articles of Association
      Insider administration
      Disclosure policy
      Transcations of managers
  • Investors
    Investors Investerare Sijoittajat
    • Financial Reports and Presentations
      Press releases
      Subscribe
    • Share and shareholders
      Share information
      Share capital development
      Certified Adviser
      Analyst Coverage
      Ownership structure
      Notifications of major shareholdings
      Manager Transactions
    • IPO 2020
    • Investor calendar
      Contact
    • Finansiella rapporter och presentationer
      Pressmeddelanden
      Prenumerera
    • Aktien och aktieägare
      Aktieinformation
      Aktiekapitalets utveckling
      Certified Adviser
      Analytiker
      Ägarstruktur
      Anmälan om betydande aktieägare
      Transaktioner utförda av personer i ledande ställning
    • Börsnotering
    • Investerarkalender
      Kontakt
    • Taloudelliset raportit ja esitykset
      Tiedotteet
      Tilaaminen
    • Osake ja osakkeeomistajat
      Tiedot osakkeesta
      Osakepääoman kehitys
      Hyväksytty neuvonantaja
      Analyytikot
      Omistusrakenne
      Ilmoitukset merkittävistä osakkeenomistajista
      Johtohenkilöiden liiketoimet
    • Listautuminen
    • Sijoittajakalenteri
      Yhteystiedot
  • Media
    Media
    • Press releases
      News
      Case studies
    • Pharmaceutical events
      Articles & videos
    • Subscribe
      Brochure
    • Contact
  • Careers
  • Contact

Press releases

All releases
  • Regulatory Releases
  • Press Releases
All years
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
All categories
  • Manager Transactions
All languages
  • English
  • Finnish
  • Swedish
Regulatory
January 11, 2023

Share subscriptions based on Nanoform Finland Plc’s stock options 3-5/2019 and 1/2020

Regulatory
January 11, 2023

Nanoform Finland Plc – Manager’s transactions – Antonio da Silva

Regulatory
December 20, 2022

Nanoform appoints Antonio da Silva as Chief of Business Operations (CBO) and member of the Management Team

Regulatory
December 20, 2022

Nanoform CTO Niklas Sandler transitions to technology advisor to the CEO

Regulatory
December 7, 2022

Nanoform financial calendar for 2023

Regulatory
November 29, 2022

Nanoform Q3 and 9M 2022 report: Continued solid progress

Non Regulatory
November 15, 2022

Invitation to Nanoform’s Interim Report January-September 2022

Regulatory
October 27, 2022

Nanoform Finland Plc – Manager’s transactions – Niklas Sandler

Non Regulatory
October 17, 2022

TargTex to present Tumour Eradication in Rodents from its Nanoformed Glioblastoma drug

Regulatory
September 7, 2022

Nanoform Finland Plc – Manager’s transactions – Niklas Sandler

Regulatory
September 6, 2022

Share subscriptions based on Nanoform Finland Plc’s stock options 2-3/2019 and 1/2020

Regulatory
August 25, 2022

Nanoform Q2 and H1 2022 report: Strong momentum continues

Non Regulatory
August 10, 2022

Invitation to Nanoform’s Interim Report January-June 2022

nanoform-1
Non Regulatory
July 14, 2022

Nanoform and Pharmanovia to breathe new life into iconic medicines

Regulatory
June 13, 2022

Nanoform Chief of Business Operations Gonçalo Andrade steps down

Regulatory
June 13, 2022

Nanoform Finland Plc – Manager’s transactions – Albert Hæggström

Regulatory
June 13, 2022

Nanoform Finland Plc – Manager’s transactions – Miguel Calado

Regulatory
June 13, 2022

Nanoform Finland Plc – Manager’s transactions – Jeanne Thoma

Regulatory
June 13, 2022

Nanoform Finland Plc – Manager’s transactions – Mads Laustsen

Regulatory
June 6, 2022

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Regulatory
June 6, 2022

Nanoform Finland Plc – Manager’s transactions – Miguel Calado

Regulatory
June 6, 2022

Share subscriptions based on Nanoform Finland Plc’s stock options 1-2/2019 and 1/2020

Regulatory
June 2, 2022

Nanoform Finland Plc – Manager’s transactions – Niklas Sandler

Regulatory
May 30, 2022

Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade

Regulatory
May 24, 2022

Nanoform 1Q 2022 report: Quarterly record of new projects and new customers

Non Regulatory
May 10, 2022

Invitation to Nanoform’s Interim Report January-March 2022

nanoform-6
Non Regulatory
May 4, 2022

Nanoform launches “STARMAP[®] Online” placing AI-power at the fingertips of medicine developers

Regulatory
April 12, 2022

Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade

Regulatory
April 12, 2022

Nanoform Finland Plc – Manager’s transactions – Niklas Sandler

Regulatory
April 12, 2022

Share subscriptions based on Nanoform Finland Plc’s multiple Stock Option Programs

Regulatory
April 12, 2022

Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc

Regulatory
April 12, 2022

Resolutions of Nanoform Finland Plc’s Annual General Meeting on April 12, 2022

Regulatory
March 25, 2022

Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade

Regulatory
March 23, 2022

New shares of Nanoform registered with the trade register

nanoform-usa-finland
Regulatory
March 22, 2022

Nanoform successfully completes new share issue raising EUR 25 million to prepare for GMP manufacturing in the USA

Regulatory
March 22, 2022

Nanoform announces its intention to carry out a new share issue to raise approximately EUR 25 million to prepare for GMP manufacturing in the USA

Regulatory
March 17, 2022

Notice to the Annual General Meeting of NANOFORM FINLAND Plc

Regulatory
March 17, 2022

Kutsu Nanoform Finland Oyj:n varsinaiseen yhtiökokoukseen

Regulatory
February 22, 2022

Nanoform 4Q and full year 2021 report: accelerating GMP growth

Non Regulatory
February 8, 2022

Invitation to Nanoform’s Q4 and full year 2021 report February 22, 2022

Non Regulatory
February 4, 2022

Nanoform signs GMP manufacturing program with TargTex following formulation success

Regulatory
January 3, 2022

Nanoform sets two new near-term business targets for 2022

Regulatory
December 10, 2021

Nanoform financial calendar for 2022

Regulatory
November 25, 2021

Nanoform Interim Report January – September 2021

Regulatory
November 17, 2021

Resolutions of Nanoform Finland Plc’s Extraordinary General Meeting on November 17, 2021

nanoform-4
Non Regulatory
November 17, 2021

Nanoform wins Star of Innovation award at the European Small and Mid-Cap Awards 2021

Regulatory
November 15, 2021

Nanoform signs GMP agreement and achieves near-term business target

Non Regulatory
November 12, 2021

Nanoform receives ISO/IEC 27001:2013 certification for its Information Security Management System

Non Regulatory
November 11, 2021

Invitation to presentation of Nanoform’s Q3/2021 report on November 25, 2021

Regulatory
October 18, 2021

Nanoform convenes EGM to elect Jeanne Thoma as board member

Regulatory
October 18, 2021

Notice to the Extraordinary General Meeting of NANOFORM FINLAND PLC

Regulatory
October 18, 2021

Kutsu Nanoform Finland OyJ:n ylimääräiseen yhtiökokoukseen

nanoform-3
Non Regulatory
September 29, 2021

Nanoform receives funding to solve challenges for global health

Regulatory
September 24, 2021

Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade

Non Regulatory
September 23, 2021

Nanoform shortlisted for the European Small and Mid-Cap Awards 2021

nanoform-2
Non Regulatory
September 9, 2021

Nanoform technology delivers successful results for Herantis CDNF drug candidate

Regulatory
August 27, 2021

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Regulatory
August 26, 2021

Nanoform Interim Report January – June 2021

Non Regulatory
August 12, 2021

Invitation to presentation of Nanoform’s Q2/2021 report on August 26, 2021

nanoform-5
Non Regulatory
August 3, 2021

Nanoform and Boehringer Ingelheim execute master services agreement

Regulatory
June 14, 2021

Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade

Regulatory
June 11, 2021

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Regulatory
June 11, 2021

Share subscriptions based on Nanoform Finland Plc’s multiple Stock Option Programs

Regulatory
June 2, 2021

Nanoform raises its mid-term business targets for 2025

Regulatory
May 27, 2021

Nanoform Interim Report January – March (Q1) 2021

Non Regulatory
May 25, 2021

Nanoform and Celanese Explore Ways to Enhance Drug Delivery

Regulatory
May 20, 2021

Cynthia Schwalm transitions to Senior Advisor Business Development US, from her role as member of the Board of Directors

Non Regulatory
May 18, 2021

Nanoform’s final clinical results confirm value proposition to the pharma industry

Non Regulatory
May 12, 2021

Invitation to presentation of Nanoform’s Q1/2021 report on May 27, 2021

Regulatory
May 11, 2021

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Non Regulatory
April 21, 2021

Nanoform and Aprecia collaborate to advance 3D printed Nanomedicines

Regulatory
April 8, 2021

Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade

Regulatory
April 7, 2021

Share subscriptions based on Nanoform Finland Plc’s multiple Stock Option Programs

Regulatory
April 6, 2021

Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc

Regulatory
April 6, 2021

Resolutions of Nanoform Finland Plc’s Annual General Meeting on April 6, 2021

Non Regulatory
March 31, 2021

Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept (“PoC”) Agreement for Two Ophthalmic Drug Candidates

Non Regulatory
March 22, 2021

Nanoform launches next-generation STARMAP® v2.0, the AI-based drug candidate selection tool for CESS®

Regulatory
March 10, 2021

NOTICE TO THE ANNUAL GENERAL MEETING OF NANOFORM FINLAND PLC

Regulatory
March 10, 2021

Kutsu Nanoform Finland Oyj:n varsinaiseen yhtiökokoukseen

Regulatory
March 10, 2021

Nanoform Finland Plc: 5 633 803 new shares registered with the trade register

Regulatory
March 9, 2021

Nanoform Finland Plc successfully completes new share issue raising EUR 40 million

Regulatory
March 9, 2021

Nanoform Finland Plc announces its intention to carry out a new share issue to raise approximately EUR 40 million

Regulatory
February 26, 2021

Nanoform 1-12/2020 report and new company near-term target introduced

Regulatory
February 26, 2021

Nanoform sets new near-term business target for 2021 and 2022

Regulatory
February 24, 2021

Additional Positive Interim Results from Nanoform’s Clinical Study

Non Regulatory
February 12, 2021

Invitation to presentation of Nanoform’s year-end report for 2020 on February 26, 2021

Non Regulatory
February 9, 2021

Nanoform and Herantis sign Biologics Proof of Concept Agreement

Regulatory
January 22, 2021

Nanoform’s Clinical Study Indicates Positive Interim Results

Non Regulatory
January 11, 2021

Finnish Foundation for Share Promotion and Nasdaq Helsinki has chosen Nanoform as the company of the month (article in Finnish)

Regulatory
January 4, 2021

Nanoform sets a new near-term business target for 2021

Non Regulatory
December 23, 2020

Nanoform included in Nasdaq First North 25 index as of Jan 4th, 2021

Non Regulatory
December 21, 2020

First dosing of nanoformed drug successfully accomplished

Regulatory
December 17, 2020

Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules

Non Regulatory
December 8, 2020

Notification of major shareholdings according to Nanoform’s Articles of Association

Non Regulatory
December 2, 2020

Nanoform makes US TV debut in Advancements with Ted Danson (CNBC)

Regulatory
November 27, 2020

Nanoform Finland Plc, Interim Report January – September 2020, November 27[th], 2020 at 08:00 a.m. Finnish time

Regulatory
November 27, 2020

Nanoform launches technology for biologics and sets new near-term business target for 2021

Non Regulatory
November 16, 2020

Invitation to presentation of Nanoform’s Q3 Report on November 27

Non Regulatory
November 11, 2020

Nanoform to present at Avanza Börsdag on November 18

Regulatory
October 23, 2020

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Regulatory
October 20, 2020

Nanoform initiates GMP campaign for first-in-human trial of nanoformed drug by year end – ahead of schedule

Regulatory
September 2, 2020

Nanoform Finland Plc – Manager’s transactions – Goncalo Andrade

Regulatory
September 2, 2020

Share subscriptions based on Nanoform Finland Plc’s 2/2019 and 1/2020 Stock Option Programs

Non Regulatory
September 1, 2020

Nanoform expands global commercial team with US appointments

Regulatory
September 1, 2020

Resolutions of Nanoform Finland Plc’s Extraordinary General Meeting and Board of Directors on September 1, 2020

Regulatory
August 28, 2020

NANOFORM FINLAND PLC, 2020 HALF YEAR FINANCIAL REPORT, 28 AUGUST 2020 AT 8:10 AM EEST

Regulatory
August 6, 2020

Kutsu Nanoform Finland OyJ:n ylimääräiseen yhtiökokoukseen

Regulatory
August 6, 2020

Notice to the extraordinary General Meeting of NANOFORM FINLAND PLC

Regulatory
August 6, 2020

Nanoform convenes EGM to elect Cynthia Schwalm as board member

Non Regulatory
July 9, 2020

Nanoform’s positive commercial momentum continues

Regulatory
June 25, 2020

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Non Regulatory
June 15, 2020

Nanoform Finland Plc appoints Peter Hänninen as General Counsel

Regulatory
June 10, 2020

Nanoform Finland Plc – Manager’s transactions – Edward Hæggström

Regulatory
June 10, 2020

Nanoform Finland Plc – Manager’s transactions – Albert Hæggström

Regulatory
June 10, 2020

Exercise of over-allotment option in relation to the initial public offering of Nanoform Finland Plc and termination of the stabilization period

Regulatory
June 10, 2020

Nanoform Finland Oyj:n listautumisannin lisäosakeoption toteuttaminen ja vakauttamisajan päättäminen

Regulatory
June 10, 2020

Utnyttjande av övertilldelningsoptionen i noteringen av Nanoform Finland Plc och avbrytande av stabiliseringsperioden

Regulatory
June 9, 2020

De tio största aktieägarna i Nanoform Finland Plc efter genomförandet av noteringen

Regulatory
June 9, 2020

Nanoform Finland Plc’s ten largest shareholders after the completion of the Initial Public Offering

Regulatory
June 9, 2020

Nanoform Finland Oyj:n kymmenen suurinta osakkeenomistajaa listautumisannin päättymisen jälkeen

Regulatory
June 3, 2020

Erbjudandet i samband med noteringen av Nanoform har kraftigt övertecknats och kommer att genomföras som planerat – handel i aktierna förväntas inledas imorgon

Regulatory
June 3, 2020

The IPO of Nanoform has been considerably oversubscribed and the listing will be completed as planned – trading in the shares is expected to commence tomorrow

Regulatory
June 3, 2020

Nanoformin listautumisanti on huomattavasti ylimerkitty ja listautuminen toteutetaan suunnitellusti – osakkeiden kaupankäynnin odotetaan alkavan huomenna

Regulatory
June 2, 2020

The institutional offering of Nanoform has been considerably oversubscribed and therefore the subscription period has been closed

Regulatory
June 2, 2020

Nanoformin Instituutioanti on huomattavasti ylimerkitty ja tämän takia merkintäaika on päätetty

Regulatory
June 2, 2020

Det institutionella erbjudandet i Nanoform är kraftigt övertecknat och teckningsperioden har därmed avslutats

Regulatory
June 1, 2020

Nanoformin Yleisöanti on huomattavasti ylimerkitty ja tämän takia merkintäaika on päätetty

Regulatory
June 1, 2020

Erbjudandet i samband med noteringen av Nanoform är kraftigt övertecknat och teckningsperioden har därmed avslutats

Regulatory
June 1, 2020

Public offering of Nanoform has been considerably oversubscribed and therefore the subscription period has been closed

Regulatory
May 28, 2020

Nanoform Finland Plc har ansökt om upptagande till handel av dess aktier på Nasdaq First North Premier Growth Market Finland och Nasdaq First North Premier Growth Market Sweden

Regulatory
May 28, 2020

Nanoform Finland Oyj on hakenut osakkeidensa listausta Nasdaq First North Premier Growth Market Finlandissa ja Nasdaq First North Premier Growth Market Swedenissä

Regulatory
May 28, 2020

Nanoform Finland Plc has applied for its shares to be listed on Nasdaq First North Premier Growth Market Finland and Nasdaq First North Premier Growth Market Sweden

Regulatory
May 25, 2020

Nanoform offentliggör en fast teckningskurs och publicerar ett prospekt för den planerade parallellnoteringen av dess aktier på Nasdaq First North Premier Growth Market i Finland & Sverige

Regulatory
May 25, 2020

Nanoform julkistaa suunnitellun listautumisantinsa kiinteän merkintähinnan sekä esitteen liittyen kaksoislistautumiseensa Nasdaq First North Premier Growth Market -markkinapaikoille Suomessa ja Ruotsissa

Regulatory
May 25, 2020

Nanoform announces a fixed subscription price and publishes a prospectus for its contemplated IPO and dual listing of its shares on Nasdaq First North Premier Growth Markets in Finland & Sweden

Regulatory
May 11, 2020

Nanoform intends to launch an initial public offering and dual listing on Nasdaq First North Premier Growth Markets in Finland & Sweden

Regulatory
May 11, 2020

Nanoform avser att genomföra ett erbjudande och att parallellnoteras på Nasdaq First North Premier Growth Market i Finland & Sverige

Regulatory
May 11, 2020

Nanoform harkitsee listautumisantia ja kaksoislistautumista Nasdaq First North Premier Growth Market Finland ja Sweden -markkinapaikoille

Non Regulatory
May 4, 2020

Nanoform awarded GMP certification

Non Regulatory
April 9, 2020

Nanoform appoints Miguel Calado as Chairman of the Board

Non Regulatory
March 9, 2020

Nanoform and Orion collaborate on next-generation drug development

Non Regulatory
February 10, 2020

Nanoform establishes US subsidiary

Non Regulatory
December 20, 2019

Nanoform files for GMP certification

Non Regulatory
November 6, 2019

Nanoform wins the CPhI Excellence in Pharma Award for Formulation

Non Regulatory
September 25, 2019

Nanoform and AstraZeneca Initiate Technology Evaluation

Non Regulatory
September 10, 2019

Nanoform strengthens board with appointment of Mads Laustsen

Non Regulatory
September 3, 2019

Nanoform appoints Mike Rea as Strategic Innovation Advisor

Non Regulatory
July 10, 2019

Nanoform appoints Director of Investor Relations following international growth

Non Regulatory
July 3, 2019

Nanoform continues strategic growth with €10 million private placement

Non Regulatory
June 27, 2019

Nanoform announces major rebrand

Non Regulatory
May 28, 2019

Nanoform accelerates growth with Director of Project Management appointment

European-Commission-award
Non Regulatory
May 28, 2019

Nanoform awarded with a Seal of Excellence from the European Commission

Non Regulatory
April 29, 2019

Nanoform strengthens GMP capabilities with Head of Manufacturing appointment

Non Regulatory
April 2, 2019

Nanoform strengthens board with appointment of Vice Chairman

Non Regulatory
March 5, 2019

Construction of Nanoform’s GMP manufacturing plant rapidly progresses

Non Regulatory
January 28, 2019

Nanoform signs world-leading sparse data AI expert

Non Regulatory
January 14, 2019

Nanoform set to boost world-class nanonization services with appointment of Chief Technology Officer

Non Regulatory
January 7, 2019

Nanoform significantly strengthens commercial organisation with Chief of Business Operations appointment

Non Regulatory
December 10, 2018

Nanoform continues rapid expansion with construction of GMP manufacturing plant

Non Regulatory
October 29, 2018

Nanoform set to globalize its technology with appointment of a Chief Commercial Officer

Non Regulatory
September 19, 2018

Nanoform set to transform drug development through €7 million investment in patented nanoparticle technology

Contact us

+358 29 370 0150
[email protected]

  • Privacy notice
  • Cookies

Subscribe

Read more about our protection of your personal data.

Nanoform Finland Oyj
Cultivator II, Viikinkaari 4
FI-00790 Helsinki
Finland
Company number: 2730572-8